Abstract: The invention relates to a gastroenteric composition comprising a compound of monomeric (+)-catechin and at least one basic amino acid or at least one derivative of a basic amino acid, said compound being in the form of a complex having a molar equivalence ratio of said monomeric (+)-catechin to said at least one basic amino acid or its derivative of between 1:1 and 1:2.5, preferably between 1:1 and 1:2.

Abstract: The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Abstract: The present invention relates to a stable pharmaceutical composition comprising azacitidine or its pharmaceutically acceptable salts, one or more sugar alcohols and one or more pharmaceutically acceptable excipients, wherein said composition is suitable for parenteral administration. The invention also relates to processes for preparing the preparation of such reconstitutable formulations. The invention also relates to therapeutic methods of use of such formulations and to use of such formulations in the manufacture of medicaments.

Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.

Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.

Abstract: Provided is a composition for hot melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6. Further, provided is a method for producing a hot melt extrudate including the step of hot melt-extruding a composition for hot melt extrusion including a drug and hypromellose acetate succinate having a molar hydroxypropoxy substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6, at a hot melt temperature of not lower than a melting temperature of the hypromellose acetate succinate or of not lower than a temperature at which both the hypromellose acetate succinate and the drug are melted.

Abstract: The present invention provides compositions and methods that promote wound healing in a subject with a cutaneous injury. In particular, the present invention provides systemic and/or local administration of one or more compositions that cause ganglioside depletion (e.g., glucosylceramide synthase (GCS) inhibitors) for the treatment of cutaneous wounds.

Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.

Abstract: Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of I?I, wherein the transfer of the heavy chain of I?I is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of I?I, wherein the transfer of the heavy chain of I?I is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof.

Abstract: The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.

Abstract: Water soluble biodegradable polymers were prepared by an organoacid catalyzed ring opening polymerization (ROP) of a cyclic carbonate monomer bearing an active ester side chain. The initial polymer comprising an active ester side chain was treated with an amino-alcohol, which transformed the active ester groups to N-substituted amide groups bearing mono-hydroxy alkyl groups and/or dihydroxy alkyl groups, thereby forming the water soluble polymers. The water-soluble polymers are non-toxic and exhibit stealth properties in buffered serum solution.

Abstract: A dasatinib and nonlinear configuration polyethylene glycol conjugate represented by formula I, wherein core is the core structure of a nonlinear configuration of polyethylene glycol, selected from a residue of pentaerythritol, methylglucoside, sucrose, diethylene glycol, propanediol, glycerol or polyglycerol removaed the hydrogen atom from the hydroxyl group; P is a polyethylene glycol residue with a number-average molecular weight of 300-60000 Da; X is selected from single bond, —CH2CO—, —CH2CH2OCO— or CH2CH2NHCO—; and i is selected from 3, 4, 6 or 8.

Abstract: A first aspect of the invention relates to a conjugate including mannan and at least one epitope comprising a peptide fragment of a protein selected from myelin basic protein (MBP), myelin oligodentrocyte glycoprotein (MOG) and proteolipid protein (PLP), said peptide fragment being in linear or cyclic form; and wherein said epitope is linked to mannan via a [(Lys-Gly)n] bridge, where n is an integer from 1 to 10. Further aspects of the invention relate to pharmaceutical compositions comprising said conjugates, and their use in the preparation of a medicament for treating an immune disorder.

Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.

Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.

Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.

Abstract: The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an anthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin (P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. Neoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer therapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred embodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is successful in treating cancers that are resistant to standard treatments, such as triple-negative breast cancer (TNBC).

Abstract: In various embodiments a payload molecule or drug molecule delivery system is disclosed for delivering paclitaxel. The system comprises a plurality of functionalized discrete carbon nanotubes having specific properties. The composition can comprise a plurality of discrete carbon nanotubes that have at least a portion of the carbon nanotubes with a number average (ratio of number average contour length to end to end length) of greater than 1.1 and up to about 3. These discrete carbon nanotubes having the specified ratio of number average (tube contour length (TCL) to number average tube end-end length (TEE)) ratio are not only discrete (separated) from one another, but are also controlled in their alignment such that processability and mechanical strength properties are both enhanced. Utility of the molecular rebar composition includes, but is not limited to improved payload molecule delivery, such as drug delivery, into body of an animal, such as human.

Abstract: Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: Agents and methods for visualization and removal of foreign material from tissue have been described. The techniques include selection of an appropriate visualization agent, treating the wound with the visualization agent and observing the wound, illuminating the wound with lighting specific to the particular visualization agent and material and viewing the illuminated wound through an optical filter specific to the wavelength of light emitted by the visualization agent.

Abstract: The present application relates to compositions comprising an iodinated contrast agent and indocyanine green co-encapsulated inside a liposomal carrier, various uses thereof as well as methods for their preparation.

Abstract: A method for magnetic resonance (MR) imaging or spectroscopy on a MR scanner to detect tissue physiological parameters in one or more tissue areas in a human or non-human subject includes administering to the subject a contrast enhancing physiologically tolerable amount of a sugar that is non-labeled, subjecting the subject to an MR procedure capable of generating MR signals encoding at least one tissue area in the subject in which the sugar either passes or is taken up, detecting a temporal variation in the MR signals in the at least one tissue area after the administering the sugar, determining at least one tissue-related parameter from the temporal variation, and ascertaining whether the at least one tissue-related parameter is abnormal.

Abstract: The present invention pertains generally to the field of imaging compounds, and more specifically to certain 2,2-dialkyl radionuclide-labelled carboxylic acids suitable for PEWT, SPECT and/or DNP imaging. Also described are uses of such compounds in the imaging of, inter alia, cancer tumors, metastasis, Alzheimer's disease and multiple sclerosis.

Abstract: A method for the disinfection of spaces and surfaces, including the steps of preparing a diffuser device equipped with a tank containing a liquid solution and nebulising means associated with the tank and designed for drawing out the liquid solution from the tank spraying it in the space, nebulising in the room a predetermined quantity of liquid solution for an interval of time and subsequent nebulising in the room a predetermined quantity of a liquid substance, different from the liquid solution and having a predetermined fragrance, following an interval of time.

Abstract: The sanitizing device for tool and cart handles is designed to rest on a base mount attached to the tool handle. When the user wants to use the sanitizing device they move the device from its rest position, spray sanitizing solution onto the desired surface area of the tool or cart handle, then slide the device along the handle to sanitize and/or disinfect it. The device includes a sponge which aids in the thorough sanitization of the desired surface area. In addition to sanitizing tool or cart handle, the device allows the user to direct the sanitizing spray into their hands to eliminate or minimize the transfer or spread of communicable pathogens. The fluid reservoir may be refillable or, alternatively, the fluid reservoir may be disposable and replaceable when the fluid is depleted.

Abstract: A method for multi-agent dry fogging. The method includes pressurizing a first agent to a first range of pressure. The first agent includes a sterilant. The method also includes pressurizing a second agent to a second range of pressure. The second agent includes a non-depleting solution for protection against microorganism growth. The method also includes pressurizing a gas to a gas range of pressure. The method also includes atomizing the first agent at a nozzle to mix with the pressurized gas in a first application stage to disperse the first agent in a first dry fog within an ambient environment. The method also includes atomizing the second agent at the nozzle to mix with the pressurized gas in a second application stage to disperse the second agent in a second dry fog within the ambient environment.

Abstract: A method to condition the air in a bowling alley utilizes an oil mixture which is dispensed by conditioning apparatus which down and up a synthetic bowling lane. The oil mixture comprises original lane oil and a fragrance composition which admixed to the oil mixture to produce a fragrant lane oil which has at 1700 cm?1 a % T which is generally equivalent to the % T of the original lane oil.

Abstract: Systems, methods, and apparatuses for increasing liquid absorption are described. Some embodiments may include a dressing having an absorbent layer containing super-absorbent material as well as ionic-exchange media (IEM). In some embodiments, the absorbent layer may include absorbent fibers. The absorbent fibers may each include a super-absorbent core surrounded by a water-permeable layer onto which ionic-exchange media (IEM) may be grafted. As liquid comes into contact with the IEM, its ionic nature may be reduced, therefore protecting the absorbent qualities of the super-absorbent material.

Abstract: Disposable absorbent articles assembled from a collection of components using an adhesive comprising an amorphous polyolefin composition and a heterophase polyolefin composition comprising amorphous character and crystalline blocks.

Abstract: A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site.

Abstract: Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads. Also provided are methods for using the compositions to repair or ameliorate damaged or defective organs or tissues.

Abstract: A firm but pliable medical device for use as a bone graft substitute or bone graft extender retains its shape without the requirement of a containment device, such as a syringe. Because the device is solid, it is easy to locate or position in-vivo and, in the moist environment of the body, it will hold its shape well, for an extended time. Because the lyophilized pliable medical device is porous, it adsorbs blood and other beneficial cells containing body fluids, such as bone marrow, contributing to its superior bone repair efficacy in comparison to an analogous putty that has not been lyophilized. In addition these lyophilized pliable medical devices are easier to terminally steam sterilize than the analogous putty because there is no moisture present to boil and ‘blow-out’ of the containment device (syringe). The glycerin that is present in the formulation lends pliability but has a low vapor pressure.

Abstract: The invention provides a method for producing an implant from interstitial, connective or supporting tissue, the method comprising at least one step of perfusing the tissue with at least one decellularisation medium under negative pressure applied for substantially the whole time period of the perfusion.

Abstract: A method of treating a biological tissue for biological prostheses includes steps of fixation of the biological tissue via a fixing solution including glutaraldehyde and detoxification of the fixed biological tissue via treatment with a detoxifying solution. The detoxification step includes one or both of eliminating phospholipids via treatment with an elimination solution and a treatment with a detoxifying solution. The elimination solution includes 1,2-octanediol and ethanol. The detoxifying solution includes taurine or homocysteic acid.

Abstract: The presently disclosed subject matter focuses on recapitulating the heterotypic interactions needed to maximize the co-development of vasculature and bone. More particularly, the presently disclosed subject matter explores the potential of cellular aggregation and temporal presentation of factors to induce the cell-cell signaling events required to stimulate ASCs to self-organize into vascularized bone. Further, exogenous PDGF-BB synergizes complex tissue formation in ASC cultures by enhancing vascular stability and osteogenic differentiation. The presently disclosed approach provides a robust protocol to engineer vascularized bone with ASCs in vitro.

Abstract: The present invention relates to an article fabrication system having a plurality of material deposition tools containing one or more materials useful in fabricating the article, and a material deposition device having a tool interface for receiving one of the material deposition tools. A system controller is operably connected to the material deposition device to control operation of the material deposition device. Also disclosed is a method of fabricating an article using the system of the invention and a method of fabricating a living three-dimensional structure.

Abstract: The present invention is related to scoring or cutting balloon catheters carrying at least on a portion of their surface at least one drug or drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein a combination of the at least one drug being a limus drug and the at least one lipophilic antioxidant being butylated hydroxytoluene is excluded.

Abstract: The present invention relates to systems for and corresponding methods of delivering a therapeutic agent to a vessel wall of a body lumen by providing a compound capable of being crosslinked after intraluminal release onto a vessel wall so that the therapeutic agent is temporarily retained at the site of delivery by the crosslinked compound.

Abstract: An object of the present invention to provide an antiadhesive material designed to have time-varying fluidity as it exhibits a gel form of high fluidity at the time of administration, and exhibits a gel form of low fluidity after it is administered to an incised and sutured site. A powdery antiadhesive material to be mixed with an aqueous solvent upon use containing alginic acid and/or a salt thereof, that is configured to be mixed with the aqueous solvent upon use so that the viscosity at 37° C. is less than or equal to 70 mPas·s at the time of 5 minutes after mixing with the aqueous solvent, and the viscosity at 37° C. is more than or equal to 120 mPas·s at the time of 60 minutes after mixing, will have high fluidity at the time of administration when it is mixed with an aqueous solvent upon use in a clinical scene, and have low fluidity after it is administered to an incised and sutured site, and thus is capable of satisfying both the excellent operability and the antiadhesive effect.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Abstract: Various irrigation fluid containment systems and components are disclosed. In some embodiments, the irrigation fluid containment system comprises a medical kit and/or an irrigation kit. In some embodiments, the irrigation fluid containment system comprises a medical basin and/or an irrigation basin. In some embodiments, the irrigation fluid containment system comprises an irrigation shield. In some embodiments, the irrigation fluid containment system comprises a suction hose.

Abstract: The present invention discloses an appliance for administering medical treatment to a person, as well as methods of using the appliance. In various embodiments, the appliance may be comprised of a medical device, an electronic processor, an electronic display (such as a liquid crystal display (LCD)), an audio output device (such as a piezoelectric speaker/microphone), electronic controls for controlling the operation of the electronic processor, and an electronic input receptacle (such as a DVD drive or USB port) adapted to receive and electronically access an electronic storage device (such as a DVD or flash memory device). The electronic processor or electronic storage device or both have information related to use and operation of the medical device digitally stored therein, so that the user of the appliance has ready access to instructional materials. Thus, the appliance includes an internal system for instructing the user in the use of the medical device.

Abstract: A method and apparatus are disclosed for providing negative pressure at a wound site. The apparatus includes a negative pressure reservoir and a reservoir valve for selectively connecting the reservoir to a wound chamber at a wound site. In particular, but not exclusively, the present invention relates to an apparatus including a source of negative pressure which acts as a negative pressure reservoir to continually or repeatedly “top up” an applied negative pressure so that negative pressure applied at a wound site can be maintained within desired limits for a relatively long period of time.

Abstract: The present invention provides hands free bra kit for removing milk from the human breast comprising an adjustable neck strap, a bottom strap, a top strap a pair of loops, a pair of tension balls and a reinforced area. The hands free bra kit is a fully portable and compact kit. The neck strap is provided around the neck, the top strap is provided around top of breast shed and the bottom strap is provided around the waist. The loop is configured for inserting horn of the breast and the tension ball holds an encircled material on the breast horn. The reinforced area can be a thicken portion or a grommet designed to take the weight of the bra kit. A method for placing hands free kit on breast and method for massaging breast to remove the milk completely is also disclosed.

Abstract: A medical device system includes a medical device configured to be carried by a patient and a plurality of controllers capable of controlling operation of the medical device. Each controller has an active state in which the controller is in communication with, and controls the operation of, the medical device, and a passive state in which the controller is not controlling operation of the medical device. At any given time only one of the plurality of controllers will be in the active state and a remainder of the plurality of controllers will be in the passive state. The active controller may be configured to continually communicate with the remainder of passive controllers, without using the medical device as an intermediary, to update the information stored in the memories of the passive controllers to match the information in the memory of the active controller.

Abstract: An oxygenator module for gas exchange between blood and a gas in an extracorporeal lung support system, with several layers of semipermeable, gas-perfusable hollow fibers, wherein the hollow fibers of one of the layers are oriented at an angle of rotation about a central longitudinal axis of the oxygenator module with respect to the hollow fibers of another one of the layers, and with a potting which extends along the central longitudinal axis and in which the hollow fibers are fixed, wherein the potting defines a cavity that extends along the central longitudinal axis and in which the hollow fibers are arranged and which is blood-perfusable in the direction of the central longitudinal axis, wherein the potting has an essentially circular inner sheath surface that limits the cavity radially outward: as well as a method for producing the oxygenator module.

Abstract: A renal therapy blood cleansing system is provided. The renal therapy blood cleansing system includes a blood circuit including a blood filtering device, a therapy fluid circuit including a balance chamber configured to exchange like volumes of fresh and used therapy fluid, a first pump configured to pump fresh therapy fluid to the balance chamber, a second pump configured to pump used therapy fluid to the balance chamber, and at least one valve located downstream from the balance chamber, the at least one valve enabling fresh therapy fluid from the balance chamber to be directed selectively to (i) a flow path leading to an inlet of the blood filtering device, or (ii) a flow path leading to the blood circuit at a location upstream or downstream of the blood filtering device.

Abstract: A method and a device for monitoring an extracorporeal blood flow during an extracorporeal blood treatment with an extracorporeal blood treatment device. The extracorporeal blood treatment device may include the device for monitoring an extracorporeal blood flow. The arterial and/or venous patient access is monitored with a first and a second method, each of which there is a check for a presence of at least one criterion that is characteristic of a condition of the vascular access that is not in proper order, the criteria for the first and second methods being distinguished from one another. A blood pump, which is preferably an occlusion blood pump, is stopped once the presence of the at least one criterion of the first method has been established, while a venous cut-off unit remains open. Once the blood pump has been stopped, the presence of the at least one criterion is checked with the second method. The venous cut-off unit is not closed until the at least one criterion for the second method is present.

Abstract: A dual lumen cannula includes a first tube defining a return lumen and having a proximal end, a mid-portion and a distal end, wherein the distal end includes a return aperture. A second tube is coaxial with the first tube and has a proximal end and a distal end, wherein the distal end of the second tube is fixedly attached to the mid-portion of the first tube and wherein the distal end of the second tube includes a drainage aperture. A drainage lumen is defined by a space between the first tube and the second tube. A connector is attached to the proximal end of the second tube. The connector includes a reservoir for receiving a fluid from the proximal end of the second tube. The first tube extends through the connector and does not attach directly with the second tube at the connector, and the first tube remains substantially coaxial with the second tube throughout a length of the second tube.